NICE Approves Ruxolitinib Cream for Treating Vi...

By HEOR Staff Writer

February 25, 2026

NICE Backs Ruxolitinib Cream Vitiligo Treatment Ruxolitinib cream vitiligo therapy has received a major endorsement from the National Institute for Health and Care Excellence (NICE), w...
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implica...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leuka...
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...
Dutch Pharmacoeconomic Redesign: Streamlined Structure and Enhanced Transpare...
Revolutionizing Pharmacoeconomic Evaluations Nederland: Zorginstituut’s...
DALY Modeling Methods for Enhanced Health Economics and Policy Analysis
Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges
Implementing Health Technology Assessment in Oman
Surrogate Endpoints Guidance: New International Report Enhances HTA Practices